Conmed Corporation · NYSE:CNMD
Conmed — Q1 2025 Earnings Presentation
10 slides from Conmed's earnings presentation, Apr 30, 2025
Slide 1: Investor Presentation Q1 2025 Earnings
Investor Presentation Q1 2025 Earnings Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer April 30, 2025
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward- looking stateme
Slide 3: CONMED Vision
CONMED Vision Empower healthcare providers worldwide to deliver exceptional outcomes for patients. Focus behind the Vision People, Products, Profitability Q1 2025 Earnings Call 3
Slide 4: Objectives for Our Shareholders
Objectives for Our Shareholders • Aggregate growth and profitability over the long term to significantly increase the valuation of the company • Evolve product mix toward higher-growth, higher-margin offerings • Increase our market share in large and attractive markets • Deliver above-market revenue
Slide 5: Orthopedics: Large, Attractive Markets
Orthopedics: Large, Attractive Markets Dollar Value of 1 Market Category Description Market Size and Competitors Share Point $5.1 to $5.3 Billion Comprehensive portfolio of devices Sports for repair and healing of soft tissue ▪ Arthrex ▪ Zimmer Biomet Mar 2025 YTD ~$52M Medicine & injuries, includin
Slide 6: General Surgery: Large, Attractive Markets
General Surgery: Large, Attractive Markets Dollar Value of 1 Market Category Description Market Size and Competitors Share Point A platform of devices and accessories $1.5 to $1.7 Billion to create and enter the surgical ▪ Ethicon (J&J) ▪ Medtronic Access working space in minimally invasive ▪ Applie
Slide 7: Key Focus Areas
Key Focus Areas AirSeal – Clinical Insufflation Buffalo Filter – Smoke Evacuation • Continuing to see double-digit demand in 2025 • Proprietary filtration technology continues to resonate with • Clinical studies continue to highlight reduction in caregivers length of stay and reduction in post-opera
Slide 8: Q1 2025 Financial Performance
Q1 2025 Financial Performance Domestic Single-Use Products General Surgery $183.8M $276.3M $183.0M $321.3M Domestic 86% WW Orthopedic Surgery 57%/43% Single Use Capital Products International Revenue $138.3M International $137.5M Products $45.0M Worldwide CC Revenue Growth %* CC Revenue Growth %* Wo
Slide 9: 2025 Updated Financial Guidance
2025 Updated Financial Guidance Revenue Low Range High Range $1,350.0 million $1,378.0 million Reported revenue (~4% constant currency growth) (~6% constant currency growth) Adjusted Diluted EPS $4.60 $4.70 Total (organic constant currency) (~10% growth) (~13% growth) Estimated foreign currency impa
Slide 10: Environmental, Social and Governance
Environmental, Social and Governance Together We Are Making A Difference for a Better Tomorrow Environmental Social Governance CONMED manufacturing operations Partners with the United Way to serve In addition to oversight by the full have recycling programs including communities where we operate in